Rallybio Corp Finalizes 1-for-8 Reverse Stock Split to Maintain Nasdaq Listing
RLYB has more than doubled off its 52-week low of $0.22.
Summary
Rallybio Corp will implement a 1-for-8 reverse stock split on February 6, 2026, a crucial move to meet Nasdaq's minimum bid price requirement and prevent delisting.
Key Events · Corporate Governance and Compliance · RLYB
-
Reverse Stock Split Finalized
Rallybio Corp filed an amendment to its Certificate of Incorporation to effect a 1-for-8 reverse stock split.
-
Shareholder Approval
Stockholders approved the reverse stock split proposal at a Special Meeting held on January 26, 2026, following the DEF 14A filing on January 2, 2026.
-
Effective Date
The reverse stock split will be effective at 12:01 a.m. ET on February 6, 2026, with post-split trading commencing the same day.
-
Nasdaq Compliance
This action is critical for the company to regain compliance with Nasdaq's minimum bid price requirement, as its stock currently trades below $1.
Analysis · RLYB · Life Sciences
Rallybio Corp has finalized a 1-for-8 reverse stock split, effective February 6, 2026, following shareholder approval. This action is a critical step for the micro-cap company to regain compliance with Nasdaq's minimum bid price requirement, as its stock currently trades below $1. While reverse splits are often viewed negatively as they reflect a low share price, this move is necessary to avoid potential delisting, which would severely impact liquidity and investor access. Investors should monitor the post-split trading and the company's ability to sustain its share price above the minimum threshold.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $0.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.2M. The 52-week trading range was $0.22 to $0.95. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.